Patients with Gal-3 values < 19.0 ng/mL treated with rosuvastatin showed a decreased risk of the primary endpoint (i.e., cardiovascular death, myocardial infarction, or stroke), lower total mortality and lower rate of the combined endpoint of total mortality and hospitalization for worsening HF compared to patients with Gal-3 > 19.0 ng/mL. This evidence concerns the gene LGALS3 and stroke disorder.